Myovant Selects Onco360 as Specialty Pharmacy for Orgovyx

The FDA approved Orgovyx in December 2021 to treat patients with advanced prostate cancer.

Onco360 has been selected by Myovant Sciences to be a specialty pharmacy partner for Orgovyx (relugolix), which is a gonadotropin-releasing hormone (GnRH) antagonist that is approved by the FDA for the treatment of adult patients with advanced prostate cancer.

The FDA approved Orgovyx in December 2021. The therapy blocks the pituitary gland from making luteinizing hormone and follicle-stimulating hormone, thereby reducing the amount of testosterone the testicles are able to make. Orgovyx is commercialized by Myovant Sciences and Pfizer.

Related: FDA clears Orgovyx, the first-of-its-kind prostate cancer treatment

it is estimated that 268,490 new cases of prostate cancer will be diagnosed in 2022 with a corresponding 34,500 deaths as a result of the malignancy, according to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. Prostate cancer is the most commonly diagnosed cancer in male patients. The median age at the time of initial prostate cancer diagnosis is 67 years old with 92.5% of cases occurring in patients who are at least 55 years old.